An overview of the five versions of adalimumab currently available in the UK. These article focuses on the differences in excipients and in particular the evidence of the relationship between the presence of citrate in the formulation and the incidence of injection site reactions. The document also provides a comparison of the five brands in terms of administration devices available.
Update on development of biosimilar versions of adalimumab with particular focus on excipients and injection site reactions
David Erskine, Director, London Medicines Information Services, Specialist Pharmacy Service Published